This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2024 Mar 12;14(1):5972.

doi: 10.1038/s41598-024-56291-z.

Retraction Note: Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain

Arunoday Bhan¹, Khairul Ansari^{2

3}, Mike Y Chen², Rahul Jandial²

Affiliations

Affiliations

¹ Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA. abhan@coh.org.
² Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA.
³ Celcuity LLC, Minneapolis, MN, 55446, USA.

PMID: 38472273
PMCID: PMC10933421
DOI: 10.1038/s41598-024-56291-z

Retraction Note: Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain

Arunoday Bhan et al. Sci Rep. 2024.

. 2024 Mar 12;14(1):5972.

doi: 10.1038/s41598-024-56291-z.

Authors

Arunoday Bhan¹, Khairul Ansari^{2

3}, Mike Y Chen², Rahul Jandial²

Affiliations

¹ Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA. abhan@coh.org.
² Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA.
³ Celcuity LLC, Minneapolis, MN, 55446, USA.

PMID: 38472273
PMCID: PMC10933421
DOI: 10.1038/s41598-024-56291-z

No abstract available

PubMed Disclaimer

Retraction of

Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain.
Bhan A, Ansari K, Chen MY, Jandial R. Bhan A, et al. Sci Rep. 2021 Oct 15;11(1):16866. doi: 10.1038/s41598-021-96351-2. Sci Rep. 2021. Retraction in: Sci Rep. 2024 Mar 12;14(1):5972. doi: 10.1038/s41598-024-56291-z. PMID: 34654856 Free PMC article. Retracted.

Similar articles

Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer.
Karagöz B, Özgün A, Emirzeoğlu L, Tunçel T, Çelik S, Bilgi O, Kara K. Karagöz B, et al. J Breast Health. 2015 Jan 1;11(1):48-51. doi: 10.5152/tjbh.2014.2009. eCollection 2015 Jan. J Breast Health. 2015. PMID: 28331691 Free PMC article.
Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.
Wan X, Zheng X, Pang X, Pang Z, Zhao J, Zhang Z, Jiang T, Xu W, Zhang Q, Jiang X. Wan X, et al. Oncotarget. 2016 Jun 7;7(23):34038-51. doi: 10.18632/oncotarget.8697. Oncotarget. 2016. PMID: 27086917 Free PMC article.
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y, Lin M, Zhang J, Wang B, Tao Z, Du Y, Zhang S, Cao J, Wang L, Hu X. Lin Y, et al. Cancer Res Treat. 2020 Oct;52(4):1059-1066. doi: 10.4143/crt.2019.633. Epub 2020 Apr 24. Cancer Res Treat. 2020. PMID: 32340083 Free PMC article.
Lapatinib.
Voigtlaender M, Schneider-Merck T, Trepel M. Voigtlaender M, et al. Recent Results Cancer Res. 2018;211:19-44. doi: 10.1007/978-3-319-91442-8_2. Recent Results Cancer Res. 2018. PMID: 30069757 Review.
Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ, Kolesar JM. Tevaarwerk AJ, et al. Clin Ther. 2009;31 Pt 2:2332-48. doi: 10.1016/j.clinthera.2009.11.029. Clin Ther. 2009. PMID: 20110044 Review.

See all similar articles

Publication types

Actions

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal